Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives. Founded in 1989 in Cambridge, MA, Vertex today has research and development sites and commercial offices around the world in the United States, Canada, Europe and Australia.
In May 2011, the U.S. Food and Drug Administration (FDA) approved Vertex’s first medicine, a treatment for hepatitis C. In January 2012, Vertex received FDA approval for our medicine for cystic fibrosis. Vertex received European approval of our medicine for cystic fibrosis in July 2012.
In addition to our approved medicines, we are developing new combinations of medicines that could further advance treatment of hepatitis C and cystic fibrosis. We also have a broad pipeline of other potential new medicines currently in early and mid-stage development for diseases such as rheumatoid arthritis, influenza and other diseases.
We collaborate with some of the world’s largest pharmaceutical companies, leading nonprofit disease foundations and many of the world’s best-known academic institutions.
Vertex has continually been recognized as one of the industry’s top workplaces by leading publications such as Science Magazine, The Boston Globe, The Boston Business Journal, The San Diego Business Journal and The Scientist.